Puma Biotech (PBYI) Announces Submission of PB272 NDA to FDA for Extended Adjuvant Treatment in Certain Breast Cancer Patients

July 21, 2016 4:12 PM EDT Send to a Friend
Puma Biotechnology, Inc. (NYSE: PBYI) has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to Premium below (Free Trial) LEARN MORE

Member Login